Journal of Pharmacy Technology最新文献

{"title":"Evaluating the Effect of Concomitant Azoles on Anticoagulant Prescribing Practices in Transplant Patients: A National Survey of Clinicians.","authors":"Kristina M Burroughs, Alicia B Lichvar, Lara M Groetzinger, Edward Horn, Carlo J Iasella, Cody A Moore, Dana R Pierce, Lauren M Sacha, Ryan M Rivosecchi","doi":"10.1177/87551225251348830","DOIUrl":"10.1177/87551225251348830","url":null,"abstract":"<p><p><b>Background:</b> Patients undergoing transplantation experience higher rates of venous thromboembolism and non-valvular atrial fibrillation (NVAF) compared with the general population. Anticoagulation decisions in this patient population are complex. A national survey on direct-acting oral anticoagulant practices demonstrated significant heterogeneity, in the setting of drug-drug interactions. <b>Objective:</b> The aim of this study was to evaluate the anticoagulation practices of clinicians caring for solid organ transplant patients. <b>Methods:</b> A 15-question survey consisting of 7 demographic questions and 8 unique patient cases was distributed via email Listserv of several professional transplantation organizations. Each case question asked the participant to select an anticoagulant regimen depending on: (1) indication for anticoagulation, (2) renal function, and (3) drug-drug interactions. Participants selected one of the following options: apixaban, dabigatran, enoxaparin, rivaroxaban, warfarin, or write in an alternative option. Descriptive statistics were used to analyze survey results. <b>Results:</b> Fifty participants completed 4 or more (≥50%) of the case-based survey questions and were included in the analysis. Ninety-four percent of participants were pharmacists, representing 43 transplant centers. Fifty-one percent of responders preferred warfarin for the indication of NVAF. Apixaban was preferred in patients with new or previous deep vein thrombosis/pulmonary embolism (51%). Fifty-four percent of respondents preferred warfarin in questions in renal dysfunction. In scenarios involving a mild-moderate CYP3A4 inhibitor azole antifungal, 61% of respondents preferred apixaban, with 64% of those selecting a standard dose regimen (vs a reduced dose regimen). Participants preferred warfarin (57%) in scenarios with a strong CYP3A4 inhibitor. <b>Conclusion and Relevance:</b> The results of our survey demonstrated a high degree of variation when selecting anticoagulation strategies in complex clinical scenarios involving transplant patients.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251348830"},"PeriodicalIF":1.1,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12209238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144553827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ensifentrine: A Novel Option for Maintenance of Chronic Obstructive Pulmonary Disease.","authors":"Emily M Hitt, Alexa J Powell","doi":"10.1177/87551225251350899","DOIUrl":"10.1177/87551225251350899","url":null,"abstract":"<p><p><b>Objective:</b> The goals of this article are reviewing the clinical aspects of ensifentrine, results from the clinical trials that led to its approval and examining its potential impact on patient care to aid therapeutic decision-making. <b>Data Sources:</b> A literature search of studies took place between October 2024 and December 2024 on PubMed using the terms <i>ensifentrine, roflumilast, Ohtuvayre™</i> and <i>ensifentrine</i> chronic obstructive pulmonary disease (COPD). <b>Study selection/data extraction:</b> Phase II and III randomized controlled trials were eligible for inclusion. Pertinent clinical trials included those focusing on the use of ensifentrine in the treatment of COPD. Meeting abstracts, systematic reviews and meta-analyses were excluded from this article. <b>Data synthesis:</b> Food and Drug Administration approval for ensifentrine is based off the phase III ENHANCE clinical trials in patients with COPD. Ensifentrine demonstrated improvement in lung function and a reduction in symptoms in clinical studies with a tolerable safety profile. <b>Conclusion:</b> The development and approval of ensifentrine for the maintenance of COPD demonstrates an advancement in patient care for a disease with significant morbidity and mortality. Ensifentrine could be a viable option as adjunct therapy for patients still experiencing symptoms despite treatment with currently recommended therapies.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251350899"},"PeriodicalIF":1.1,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144506041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vamorolone Versus Traditional Glucocorticoids in Duchenne Muscular Dystrophy: A Review and Meta-Analysis of Efficacy and Safety.","authors":"Dawood Javed, Abdullah Javed, Faran Ahmed Jajja, Ahmed Jahanzeb","doi":"10.1177/87551225251349402","DOIUrl":"10.1177/87551225251349402","url":null,"abstract":"<p><p><b>Objective:</b> This meta-analysis evaluates the efficacy and safety of vamorolone, a dissociative glucocorticoid, compared with traditional glucocorticoids in treating Duchenne muscular dystrophy (DMD), aiming to assess its potential as a safer alternative with comparable therapeutic benefits. <b>Data Sources:</b> A systematic search was conducted in PubMed (MEDLINE), Embase, and Web of Science from inception till June 2024. Search terms included (Vamorolone) AND (Corticosteroids OR Glucocorticoids OR Prednisone) AND (Duchenne Muscular Dystrophy OR related terms). Only randomized controlled trials (RCTs) and observational studies were included, with no language restrictions. <b>Study Selection and Data Extraction:</b> From 276 identified reports, 135 were screened after duplicate removal, and 30 underwent full-text review. Five studies (2 RCTs, 2 observational, 1 nonrandomized trial) involving 370 patients were included. Two reviewers independently extracted data on efficacy (TTSTAND, TTRW, TTCLIMB velocities) and safety (height percentile, body mass index-z score, osteocalcin, P1NP) using Microsoft Excel, resolving discrepancies through consensus. <b>Data Synthesis:</b> Vamorolone significantly improved TTSTAND (MD = -0.03, 95% confidence interval [CI] = -0.06 to -0.004, <i>P</i> = .02), TTRW (MD = -0.11, 95% CI = -0.22 to -0.01, <i>P</i> = .04), and TTCLIMB velocities (MD = -0.04, 95% CI = -0.08 to -0.003, <i>P</i> = .03). Safety outcomes showed enhanced height percentile (MD = 16.28, 95% CI = 6.31-26.25, <i>P</i> = .001) and bone biomarkers (osteocalcin: MD = 15.68, <i>P</i> < .00001; P1NP: MD = 158.34, <i>P</i> < .00001), with no significant body mass index-z score difference. <b>Conclusions:</b> Vamorolone offers comparable efficacy with traditional glucocorticoids in DMD, with improved motor function and safer profiles in growth and bone health, suggesting its potential to transform DMD management.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251349402"},"PeriodicalIF":1.1,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144506042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of HbA1c and Continuous Glucose Monitor Time in Range.","authors":"Hannah DePasquale, Alexander DeLucenay, Nabila Ahmed-Sarwar","doi":"10.1177/87551225251348832","DOIUrl":"10.1177/87551225251348832","url":null,"abstract":"<p><p><b>Background:</b> Current literature is limited to describing the correlation of continuous glucose monitor (CGM) use and improved HbA1cs in patients with type 2 diabetes. There is a lack of literature correlating HbA1c and time in range (TIR). In addition, data such as time spent with low or very low blood glucose levels are not assessed in existing literature. <b>Objective:</b> To assess the correlation between reduction of HbA1c and increase in TIR for patients using CGMs meeting with an interdisciplinary team. <b>Methods:</b> This retrospective chart review includes adult patients seen in an interdisciplinary internal medicine clinic consisting of a pharmacist and nurse practitioner. Data collection included patients with diabetes using CGMs for at least 3 months, who had a visit with the team in the last 12 months. Information collected included demographics, insurance, comorbidities, diabetes medications, HbA1c and CGM data at baseline and 3-month visit, and number of pharmacist medication interventions. Fisher's exact, chi-square, and Mann-Whitney <i>U</i> tests were used where appropriate. <b>Results:</b> HbA1c decreased from 8.6% to 7.5% 3 months later (<i>P</i> = 0.002). The average increase in TIR was 55.5% to 65.1% (<i>P</i> = 0.007). The overall decrease in HbA1c and increase in TIR had a high inverse correlation at baseline and 3 months (<i>r</i> = -0.7 and <i>r</i> = -0.7, <i>P</i> < 0.001). <b>Conclusion:</b> There is a strong inverse relationship between HbA1c and TIR, reduction in glucose variability with a slightly higher incidence time in low/very low following intervention. The type and frequency of pharmacist-initiated interventions support the clinical decision-making potential for pharmacotherapy adjustments.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251348832"},"PeriodicalIF":1.1,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144506039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emergency Drug Box Accuracy: Analysis of Manual Replenishment Errors and the Use of RFID as a Preventative Strategy.","authors":"Mohamed Sarg, Megan Rowcliffe, Agnes Ann Feemster, E Robert Feroli, Rosemary Duncan","doi":"10.1177/87551225251344143","DOIUrl":"10.1177/87551225251344143","url":null,"abstract":"<p><p><b>Background:</b> Emergency drug boxes (EDBs) contain essential medications and supplies for use during life-threatening emergencies. Most health system pharmacies use a manual process for stocking these boxes, relying on individuals to perform the tasks. This approach is inherently prone to human error. <b>Objective:</b> To assess the accuracy of the current manual stocking process for EDBs, determine the clinical severity of any errors found, and evaluate the potential for using radio frequency identification (RFID) technology to mitigate these errors. <b>Methods:</b> This was a 2-phase retrospective study conducted at a large academic medical center. Phase 1 involved the assessment of adult and pediatric EDBs for stocking errors. Phase 2 evaluated the clinical severity of the errors discovered. The adult and pediatric Cardiopulmonary Resuscitation Committees independently ranked each identified error on a 3-point scale (1 = unlikely harm to 3 = severe discomfort or clinical deterioration). The study calculated the percentage of errors that could be detected by the implementation of RFID technology. <b>Results:</b> In total, 451 EDBs were analyzed for stocking errors. 106 (24%) contained at least one error, resulting in 132 identified errors. Implementing RFID technology would detect 96 of these 132 errors (73%). Of the detectable errors, 43 (40%) were ranked 2 or 3, indicating a higher likelihood of clinical harm or deterioration. <b>Conclusion:</b> Manual restocking and checking of EDBs are vulnerable to human error, which can have serious consequences and jeopardize patient safety. Adopting RFID technology can greatly improve the accuracy and reliability of this essential process.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251344143"},"PeriodicalIF":1.1,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144506040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pleural Effusion and Anasarca Associated With Pioglitazone.","authors":"Ashwin Jagadish, Shahnawaz Notta, Stephen Bakeler, David Joseph","doi":"10.1177/87551225251348838","DOIUrl":"10.1177/87551225251348838","url":null,"abstract":"<p><p><b>Introduction:</b> Pioglitazone is a medication that can be utilized in the management of type 2 diabetes mellitus (T2DM). It can be associated with adverse effects such as edema, weight gain, and heart failure. It is not commonly associated with pleural effusions. <b>Case Presentation:</b> Our case involves an 81-year-old man with T2DM who presented to the emergency department due to progressively worsening lower extremity edema and exertional dyspnea. These symptoms began after the patient started to regularly take pioglitazone. He had a large pleural effusion and diffuse anasarca. Pioglitazone was discontinued and he underwent successful thoracentesis and diuresis. <b>Discussion:</b> The Naranjo scale yielded a score of 7 points, indicating a probable association between pioglitazone and our patient's presentation. There is limited documentation of pleural effusions associated with pioglitazone. Our case is unique as the patient had pleural effusions and anasarca associated with pioglitazone.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251348838"},"PeriodicalIF":1.1,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12170548/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144326091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Propofol Microbial Contamination Following Treatment With Drug Disposal Devices.","authors":"Ransome van der Hoeven, Alan L Myers","doi":"10.1177/87551225251343559","DOIUrl":"10.1177/87551225251343559","url":null,"abstract":"<p><p><b>Background:</b> Pharmaceutical waste represents a major burden to the health care system and environment. Proper drug waste disposal devices are vitally needed, especially for propofol solutions that inherently carry a high risk of microbial contamination. <b>Objectives:</b> The aims of this study were to compare the capabilities of 2 drug disposal systems for decontamination of propofol solutions inoculated with medical pathogens and assess chemical degradation of propofol after treatment with Fenton reagents. <b>Methods:</b> Standard microbiological assays were used to assess survival and growth of <i>Escherichia coli</i> and <i>Candida albicans</i> inoculated into propofol solutions. Both a prototype instrument and a commercially marketed disposal device were tested for their ability to kill microbial growth. Furthermore, a propofol bioanalytical assay utilizing high-performance liquid chromatography (HPLC) was developed to measure propofol concentrations before and after treatment with a Fenton reagent cocktail (iron and hydrogen peroxide). <b>Results:</b> Propofol emulsion and diluted solutions lack antimicrobial properties and support the growth of microbes. The prototype instrument effectively killed <i>E. coli</i> and <i>C. albicans</i> inoculated into propofol solutions, while the commercial product did not kill or inhibit the growth of the microorganisms. Finally, propofol was chemically degraded to undetectable quantities (< 0.13 ppm) upon exposure to Fenton reagents in a prototype instrument. <b>Conclusions:</b> We show for the first time that propofol solutions inoculated with microbes are decontaminated upon exposure to Fenton reagents. Treatment with Fenton reagents also chemically destroys the propofol molecule. These results will support the development of novel drug disposal devices for real-time application in the pharmacy setting.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251343559"},"PeriodicalIF":1.1,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilizing Simulated Caregiver Scenarios to Cultivate Caregiver Perspectives and Empathy among Pharmacy Students within Ambulatory Care.","authors":"Bradley Phillips, Angelina Vascimini, Chris Egan, Jason Powell","doi":"10.1177/87551225251343557","DOIUrl":"10.1177/87551225251343557","url":null,"abstract":"<p><p><b>Objective:</b> To cultivate caregiver perspectives and empathy through computer-based simulations in the ambulatory care setting. <b>Methods:</b> A total of 46 third-year students were enrolled in the 2-week ambulatory care elective at the University of Florida College of Pharmacy. Students were assigned 5 computer-based simulated scenarios, each created to encompass elements regarding social determinants of health from a caregiver perspective. After each scenario, students were required to complete a post scenario assessment where students were tasked with reporting their emotional response by providing 3 adjectives upon completion. After completing all caregiver scenarios, students completed a postsimulation reflection connecting their experience with caring for their future ambulatory care patients. Both individual and final reflections were analyzed and assigned to the themes of emotional strife, compassion/understanding, self-reflection, resilience, and/or other to determine proportion of identified themes. <b>Results:</b> For the individual caregiver scenarios, the most identified theme was emotional strife amongst all scenarios (45%-68%). Regarding the final reflection, most of the theme identified were compassion/understanding (46%) followed by self-reflection (29%). Emotional strife was the least identified theme in the final reflection (7%). <b>Conclusion:</b> After students completed all the caregiver scenarios, students reported higher levels of compassion/understanding and self-reflection when compared with other identified themes. Through this computer-based simulation, students gained a better understanding and empathy toward the caregiver perspective when faced with common health care disparities in an ambulatory care patient population.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251343557"},"PeriodicalIF":1.1,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103462/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing the Dosing of Heparin for Therapeutic Anticoagulation in Neurocritical Care Patients at High Risk of Bleeding: Report on a Quality Improvement Initiative.","authors":"Sahil Kapoor, Nick Scaturo, Garrett Thompson, Benji Small, Christopher R Newey, Shayn Martin, Peter Miller, Aarti Sarwal","doi":"10.1177/87551225251343558","DOIUrl":"10.1177/87551225251343558","url":null,"abstract":"<p><p><b>Background:</b> Heparin infusions are used to treat and prevent thromboembolic complications in neurocritical care, but optimal dosing in patients with acute intracranial pathology or recent neurosurgery is uncertain, due to elevated risk of hemorrhage. Many institutions customize heparin nomograms for such patients but fail to methodically evaluate their effectiveness. <b>Context</b>: Neurocritical care unit in an academic medical center in the United States. <b>Problem:</b> Several incidents of heparin infusions failing to reach their partial thromboplastin time (PTT) goal within 24 hours of initiation occurred. This created a concern that existing heparin dosing protocol should be adjusted to attain goal PTT more rapidly to better treat thrombotic events. <b>Objective:</b> To reduce time to therapeutic effectiveness of weight-based heparin in neurocritical care patients at high risk of bleeding. <b>Study Design:</b> Quality improvement initiative, comparing data from a retrospective chart review (historical comparison cohort) and a prospective observational quality improvement initiative (QI cohort). <b>Patients:</b> Adult patients with acute intracranial pathology and acute indications for therapeutic anticoagulation but considered at high risk of intracranial hemorrhage. <b>Interventions:</b> Increase heparin dosing nomogram from 12 units/kg/h (historical cohort) to 18 units/kg/h (quality improvement cohort), without an initial bolus in either. <b>Measurements:</b> Primary endpoint was time to therapeutic activated partial thromboplastin time (aPTT) in hours, assessed with a Kaplan-Meier curve. Any known bleeding or thrombotic complications were recorded. <b>Results</b>: Time to reach therapeutic target aPTT was shorter in quality improvement cohort than in historical cohort (see Figure 1 in full text for details). Bleeding complications occurred in 3 of 21 patients in each cohort. <b>Conclusions:</b> Quality improvement initiatives such as this can make documented improvements in health care provided to neurocritical care patients.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251343558"},"PeriodicalIF":1.1,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103460/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Exposures Following Recent Demand for Weight Management: A Retrospective Review of California Poison Control System Data.","authors":"Raymond Y Ho, Hsiaoting Regelman, Anita Ma, Shu Yi Lee, Saveena Sandhu, Sarah Shapiro, Justin Lewis, Ben Tsutaoka, Dorie E Apollonio","doi":"10.1177/87551225251332212","DOIUrl":"https://doi.org/10.1177/87551225251332212","url":null,"abstract":"<p><p><b>Background:</b> Calls to poison centers involving exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RA) have increased. Data from a statewide poison control system from 2017 to 2023 was analyzed to assess changes in GLP-1 RA exposure frequencies and reported clinical effects. <b>Methods:</b> Retrospective records review of all human exposure cases to GLP-1 RA reported to a statewide poison center from December 1, 2017 to December 31, 2023. Collected data were entered into REDCap (Research Electronic Data Capture). Changes in exposure frequency over time assessed with interrupted time series analysis (ITSA); the intervention was FDA approval of semaglutide (Wegovy) for chronic weight management in June 2021. Statistical analyses completed using Stata v17 or OpenEpi (v3.01). <b>Results:</b> One thousand forty-seven cases were included. Interrupted time series analysis identified an increase in reported GLP-1 RA exposures of 1.16 per month ([CI = 0.570, 1.802]; <i>P</i> < 0.001) and an increase in hospital utilization from exposures of 0.351 per month ([CI = 0.159, 0.544]; <i>P</i> = 0.001) following Wegovy approval. Common adverse effects were nausea (n = 295, 28.0%), vomiting (n = 267, 25.5%), dizziness (n = 63, 6.0%), abdominal pain (n = 54, 5.1%), and other gastrointestinal symptoms (n = 60, 5.7%). Most cases were managed at home (n = 696, 66.5%). Two hundred twenty (21.0%) patients were treated in the emergency department, and 46 (4.4%) were admitted. The most common reason for exposure was unintentional therapeutic error (n = 838, 80.0%). Five major (0.5%) and 72 moderate (6.9%) medical outcomes were reported. Hypoglycemia occurred in 40 (3.8%) patients. Thirty-six exposures involving compounded GLP-1 RA were identified; administration errors were the main reason for exposures among this subgroup (n = 33, 91.7%). <b>Conclusion:</b> Glucagon-like peptide-1 receptor agonist exposures and hospital utilization after exposure increased following Wegovy approval for weight management. Hypoglycemia, while infrequent, was reported; nondiabetic patients using GLP-1 RA should be educated on recognizing hypoglycemia. Additional patient education on GLP-1 RA administration and further study on the impact of compounded GLP-1 RA products are warranted.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"87551225251332212"},"PeriodicalIF":1.1,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069307/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}